GOG 262: Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Weekly paclitaxel did not significantly extend progression-free survival (PFS) compared to every-3-week paclitaxel overall.
Shitanshu Uppal
GOG 172: Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
IP administration of cisplatin and paclitaxel significantly improves both progression-free and overall survival in patients with optimally debulked stage III ovarian cancer compared to standard IV therapy, despite increased toxicities.
GOG 158: Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer
The combination of carboplatin and paclitaxel is not inferior to cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. Carboplatin plus paclitaxel results in less toxicity and is easier to administer.
Publications Update # 66
Tisotumab phase 3 study, reflection as a practice to improve your career, Denosumab for prevention of bone density loss in anti-estrogen therapy, immunotherapy side effect profiles and ovarian cancer risk in endometriosis
InnovaTV 301/ENGOT-cx12/GOG-3057: Tisotumab Vedotin for Recurrent Cervical Cancer
Second- or third-line treatment with tisotumab vedotin significantly improves overall survival and progression-free survival compared to chemotherapy in patients with recurrent cervical cancer.
Ovarian Cancer - NACT vs. PDS
Publications Update # 65
GoodFellas reposted, all things ostomy and sentinel nodes in cervical cancer
CHORUS Trial: PDS vs. NACT
Primary chemotherapy followed by delayed surgery is non-inferior to primary surgery followed by chemotherapy in women with advanced ovarian cancer, with reduced surgical morbidity and mortality.
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer: EORTC Trial
Neoadjuvant chemotherapy followed by interval debulking surgery is not inferior to primary debulking surgery followed by chemotherapy in patients with bulky stage IIIC or IV ovarian carcinoma. Complete resection of all macroscopic disease remains the objective in cytoreductive surgery.